Implication of lipocalin-2 and visfatin levels in patients with coronary heart disease

K. M. Choi, J. S. Lee, E. J. Kim, S. H. Baik, H. S. Seo, D. S. Choi, D. J. Oh, C. G. Park

Research output: Contribution to journalArticle

117 Citations (Scopus)

Abstract

Objectives: Visfatin and lipocalin-2 are novel adipokines associated with insulin resistance (IR) and obesity-related metabolic disorders. We compared lipocalin-2 and visfatin concentrations between patients with coronary heart disease (CHD) and control subjects and evaluated their association with cardiovascular risk factors. Methods: We examined serum visfatin, lipocalin-2 levels, and cardiovascular risk factors in 91 subjects (49 patients with angiographically confirmed CHD versus 42 age- and gender-matched control participants). Results: Circulating lipocalin-2 levels were significantly higher in patients with CHD compared with the control subjects (82.6±38.7 ng/ml versus 43.8±27.8 ng/ml; P<0.001). However, visfatin levels were not significantly different between patients with CHD and control subjects. Serum lipocalin-2 levels were positively associated with weight (r=0.26; P=0.036), fasting insulin (r=0.36; P=0.003), and IR (r=0.33; P=0.007), whereas these levels showed a negative correlation with high-density lipoprotein (HDL) cholesterol (r=-0.30; P=0.016) after adjustment for gender and body mass index. However, visfatin levels were not associated with any variables of the metabolic syndrome. The multiple regression analysis showed that lipocalin-2 levels were independently associated with HDL cholesterol and IR (R2=0.199). Furthermore, the multiple logistic regression analysis showed that systolic blood pressure, IR, and lipocalin-2 levels were independently associated with CHD. Conclusions: Serum lipocalin-2 levels were significantly elevated in patients with CHD and were independently associated with CHD. The present findings suggest that the measurement of serum lipocalin-2 levels may be useful for assessing CHD risk.

Original languageEnglish
Pages (from-to)203-207
Number of pages5
JournalEuropean Journal of Endocrinology
Volume158
Issue number2
DOIs
Publication statusPublished - 2008 Feb

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Fingerprint Dive into the research topics of 'Implication of lipocalin-2 and visfatin levels in patients with coronary heart disease'. Together they form a unique fingerprint.

  • Cite this

    Choi, K. M., Lee, J. S., Kim, E. J., Baik, S. H., Seo, H. S., Choi, D. S., Oh, D. J., & Park, C. G. (2008). Implication of lipocalin-2 and visfatin levels in patients with coronary heart disease. European Journal of Endocrinology, 158(2), 203-207. https://doi.org/10.1530/EJE-07-0633